Neurodegeneration Breakout, KI-Mayo Meeting 2022

Program Chairs and Moderators: Dr. Christopher Schwarz, Dr. Amit Kumar, Dr. Pamela McLean and Dr. Daniel Ferreira

Neurodegeneration Breakout Session

15:30- 17:30 PM (Stockholm); 8:30- 10:30 AM (Rochester)
Welcome and Overview of Session Day One

  • Cholesterol and sex-hormones: unravelling the mechanisms behind sex differences in Alzheimer’s disease - Dr. Silvia Maioli, Assistant Professor,Karolinska Institutet

  • Impacts of Vascular ApoE2 on Cerebrovasculature and AD Pathogenesis - Miss Francis Shue, Mayo Clinic

  • Clinical Significance of Positive Tau with Negative Amyloid PET Scans - Miss Carling Robinson, B.A., Mayo Clinic                                           

  • High baseline tau load differentiates β-amyloid positive fast decliners - Dr. Konstantinos Ioannou, MD, MSc, Karolinska Institutet                                      

  • Multi-tracer comparison in Alzheimer's disease, corticobasal degeneration and progressive supranuclear Palsy brains - Miss Mona-Lisa Malarte, MSc, Karolinska Institutet                                            

  • Proximity proteomics of protein associated with poly-GA in C9-FTD/ALS  - Dr. Feilin Liu, MD, Mayo Clinic                                             

  • Clinical data collection and outcomes in Amyotrophic Lateral Sclerosis (ALS) - Dr. Björn Oskarsson, Associate Professor, Mayo Clinic                                             

    Coffee break (15 mins)

  • c-Jun-N-Terminal Kinase promotes stress granule assembly and neurodegeneration in c9orf72-mediated amyotrophic lateral sclerosis and frontotemporal dementia - Dr Sahana TalanjeriGopalakrishna, Ph.D., Mayo Clinic      

  • Amyloid-β PET in the continuum of dementia of Lewy Bodies - Dr. Patricia Diaz Galvan, PhD, Mayo Clinic                                             

  • Sex-specific differences in grey matter networks in dementia with Lewy bodies - Dr. Annegret Habich, Dr. rer. nat., Postdoc, Karolinska Institutet

  • Visual ratings of cholinergic white matter signal abnormalities in dementia with Lewy bodies - Mr. Cene Jerele, Masters of Science, Karolinska Institutet                                                     

  • Cerebrovascular burden is related to clinical phenotype in a multi-centre DLB cohort - Ms Anna Rennie, Karolinska Institutet

  • Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech - Dr Irene Sintini, PhD, Mayo Clinic

  • Diagnosis of inner ear disorders using MRI-from animal study to clinical application - Maoli Duan, MD, PhD,   Karolinska Institutet; Karolinska University Hospital

16:15- 18:15 PM (Stockholm); 9:15 - 11:15 AM (Rochester)
Welcome and Overview of Session Day Two
  • Potential for Re-Identifying Brain PET Research Participants using Face Recognition - Dr. Christopher Schwarz, PhD, Mayo Clinic              
  • CHOOSING A CROSS-SCANNER HARMONIZATION METHOD FOR sMRI: COMPARISON OF DEEP-LEARNING AND TRADITIONAL METHODS - Dr. Robel Gebre PhD, Mayo Clinic
  • Utility of Regional diffusion MRI as a surrogate marker of Cerebrovascular disease - Dr. Sheelakumari Raghavan, PhD, Mayo Clinic                                             
  •  Unravelling heterogeneity in healthy aging: longitudinal trajectories of grey matter - Giulia Lorenzon, M.Sc., Karolinska Institutet
  • Predicting Biological Brain Age using Convolutional Neural Networks - Dr. Caroline Dartora, Doctor of Science in Biomedical Gerontology, Karolinska Institutet
  • Altered within and between-network functional connectivity in logopenic progressive aphasia and posterior cortical atrophy- Dr Neha Atulkumar Singh, Ph.D, Mayo Clinic                                             
  • MRI-BASED SUBTYPES OF PARKINSON´S DISEASE ROBUSTLY IDENTIFIED IN FOUR COHORTS - Dr Anna Inguanzo, PhD, Karolinska Institutet    
  • Coffee break (15 mins)
  • Perry syndrome: another form of parkinsonism responsive to levodopa - Dr Jaroslaw Dulski, MD PhD, Mayo Clinic
  • In vivo model of the cholinergic pathways in aging and Alzheimer’s disease - Mr Milan Nemy, M.Sc., Karolinska Institutet
  • Studying cellular dynamics to optimize encapsulated cell mediated drug delivery as AD therapy - Dr. Sumonto Mitra, PhD, Karolinska Institutet            
  • TAR DNA-binding protein 43 (TDP-43) pathology effect on volume and flortaucipir uptake in Alzheimer’s disease - Dr Arenn F. Carlos, M.D., Mayo Clinic                                            
  • EVALUATION OF PERIPHERAL IMMUNE CHARACTERISTICS IN A NOVEL AppNL-G-F KNOCK-IN MOUSE MODEL OF ALZHEIMER’S DISEASE - Dr. Ruchi Gera, Ph.D., Karolinska Institutet
  • Alzheimer’s disease risk factors: age, APOE genotype, and sex drive cell-type specific gene expression changes - Dr. Yingxue Ren, Ph.D., Mayo Clinic                       
  • Multi-PET tracer approach to investigate reactive astrocytes in Alzheimer’s disease brain - Dr. Igor Fontana, PhD, Karolinska Institutet                                               

  • 18:20pm/11:20 am Transition to Fika 

  • 18:30pm/11:30 am Plenary begins

 

Pernilla Witte
02-09-2022